Advertisement
Nomad's plant-based protein expression technologies are being licensedfrom several companies for a broad range of products. NOMAD's proprietarytechnologies further improve the upstream part of the manufacturing process,but most importantly, they provide for novel downstream solutions thattogether with the in-licensed upstream components should result in a superiorfully integrated manufacturing process for most of NOMAD's intended products.Another major focus of NOMAD is innovations that provide for full integrationof the novel process components and novel product parts into existingindustrial processes/products.
Advertisement
NOMAD's biomaterial pipeline consists of several selected productcandidates, including plant-made cellulase enzymes (expected impact: up to 30%lower manufacturing cost of bioethanol), nanostructured polyadsorbents foraffinity purification of biopharmaceuticals (low cost polyaffinitynanoparticles that replace expensive current affinity resins) andnanopatterned electrodes (batteries with improved electrochemical cyclingproperties and electrode capacity).
NOMAD's pharmaceutical portfolio is focused on three 'biosimilar' versionsof the proteins currently constituting a $15 B market: Insulin, Etanercept(Enbrel(R)), and Trastuzumab (Herceptin(R)). Our lead pharmaceutical product,Insulin, targets the US$7.5 billion Insulin market. NOMAD's Insulin willprovide an economical alternative to commercially available Insulin to betterserve developing nations and meet the anticipated surge in demand. Thebiologics segment of the portfolio offers the longer term higher upsidemargins associated with pharmaceuticals while controlling the development riskthrough selection of early candidates from among 'biosimilar' products.
NOMAD intends to develop and commercialize its products in partnershipwith leading industry companies. The Company is focusing on rapidly expandingmarkets with ability and willingness to adopt new generation processes for newas well as existing products, in return for lower manufacturing costs, betterecological profiles and innovative value capture mechanisms. NOMAD's value istied to technology platforms that reduce capital and running costs of theplant-based production to new lows, diversified portfolio of carefully chosenand innovative candidates that address attractive markets, very fast R&Dengine and very short production cycle.
The founder of NOMAD is Prof. Dr. Yuri Gleba. Prior to founding NOMAD in2008, Dr. Gleba co-founded two other biotech companies, Icon Genetics(Germany, USA) and Phytomedics (USA). He has been the CEO of Icon Geneticssince its inception in 1999 and he has brought it to a successful exit in 2006by selling the company to Bayer AG; he continues to manage it now. In additionto being an entrepreneur, Dr. Gleba has over 30 years of experience insuccessful management of academic/corporate R&D projects. He is a wellrespected scientist and inventor as evidenced by his more than 200 researchpapers, books and over 30 patent families and election to six national andinternational academies of science. Over the next few months, NOMAD intends tobuild a team of managers that have the necessary qualifications.
SOURCE NOMAD Bioscience GmbH
